108 related articles for article (PubMed ID: 34897041)
1. THE QUALITY OF LIFE OF OVARIAN CANCER PATIENTS AS AN INDICATION OF THE EFFECTIVENESS OF PLATINUM-BASED ADJUVANT CHEMOTHERAPY.
Bondar O; Rybin A; Patskov A; Varabina A
Georgian Med News; 2021 Nov; (320):32-36. PubMed ID: 34897041
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
3. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
4. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
6. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
7. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of health-related quality of life after laparoscopic colectomy for cancer.
Theodoropoulos GE; Karantanos T; Stamopoulos P; Zografos G
Tech Coloproctol; 2013 Feb; 17(1):27-38. PubMed ID: 23065134
[TBL] [Abstract][Full Text] [Related]
9. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
11. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
12. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain.
Giesinger JM; Kuijpers W; Young T; Tomaszewski KA; Friend E; Zabernigg A; Holzner B; Aaronson NK
Health Qual Life Outcomes; 2016 Jun; 14():87. PubMed ID: 27267486
[TBL] [Abstract][Full Text] [Related]
13. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
14. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
15. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
Kiselev VI; Ashrafyan LA; Muyzhnek EL; Gerfanova EV; Antonova IB; Aleshikova OI; Sarkar FH
BMC Cancer; 2018 Sep; 18(1):904. PubMed ID: 30236079
[TBL] [Abstract][Full Text] [Related]
16. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany.
Hilpert F; du Bois A; Greimel ER; Hedderich J; Krause G; Venhoff L; Loibl S; Pfisterer J
Ann Oncol; 2007 Feb; 18(2):282-7. PubMed ID: 17082513
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
[TBL] [Abstract][Full Text] [Related]
18. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two quality-of-life questionnaires for cancer clinical trials: the functional living index--cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30).
King MT; Dobson AJ; Harnett PR
J Clin Epidemiol; 1996 Jan; 49(1):21-9. PubMed ID: 8598507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
